SEARCH

SEARCH BY CITATION

References

  • 1
    National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994. Hyattsville, MD: Center for Disease Control and Prevention, 1996.
  • 2
    Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 77889.
  • 3
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 148592.
  • 4
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 142632.
  • 5
    National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002; June 10–12, 2002. Final Statement. Hepatology 2002; 36(Suppl. 1): S320.
  • 6
    Cook D, Guyatt G, Laupacis A, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102(Suppl.): 305S.
  • 7
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996; 17: 112.
  • 8
    Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32: 64753.
  • 9
    Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 4338.
  • 10
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 11
    Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 166672.
  • 12
    Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 167380.
  • 13
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 14
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 15
    Muir AJ, Bornstein JD, Killenberg PG, et al. Pegylated alfa-2b and ribavirin for the treatment of chronic hepatitis C infection in African Americans and non-Hispanic whites. A preliminary report [abstract]. Gastroenterology 2002; 122: 116.